Replimune Group (NASDAQ:REPL) Trading Up 5.4% - Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares shot up 5.4% during mid-day trading on Thursday . The company traded as high as $8.61 and last traded at $8.89. 60,465 shares were traded during mid-day trading, a decline of 93% from the average session volume of 926,053 shares. The stock had previously closed at $8.43.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $19.75.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market capitalization of $738.80 million, a price-to-earnings ratio of -3.12 and a beta of 0.68. The company has a 50-day moving average of $8.39 and a 200-day moving average of $11.08.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.25) earnings per share. As a group, equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $260,168.74. Following the sale, the director now directly owns 1,405,071 shares of the company's stock, valued at $11,324,872.26. This trade represents a 2.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,952 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now directly owns 146,933 shares of the company's stock, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its holdings in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares during the period. US Bancorp DE boosted its position in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after acquiring an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd grew its holdings in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares during the period. Finally, GAMMA Investing LLC increased its position in Replimune Group by 897.2% during the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.